The European Commission announced, at the beginning of the year 2018, the launch of a European initiative. This latter was addressed to the consortium members: The Maxibone project . Mainly, ten entities from five different countries being France, Spain, Norway, Denmark, and Germany, participated in this project. Maxibone consists particularly, of various clinical and preclinical trials. Markedly, the experiments aim to validate the efficacy of different biomaterials applied to the bone. Accordingly, The EU Commission granted Mimetis 320,000 Euros for its participation.
Mimetis Part of the Clinical Validation of patient-Specific Biomaterials
With this purpose in mind, Mimetis Biomaterials continues to be part of the preclinical validation project by developing custom-made patient-specific biomaterials. In that discipline, Mimetis uses 3D micro extrusion, a three-dimensional bioprinting technique.
Similarly, one clinical trial that is part of this project explores two different treatments in terms of efficacy. It is important to note that those treatments are the application of choice in a maxillofacial case of vertical alveolar ridge augmentation. On the one hand, a bone granular biomaterial will be placed together with human stem cells (hMSC). On the other hand, the researchers will use an autograft.
Accordingly, Mimetis received 320,000 Euros in grants to carry out this study, which will take place over four years, ending in 2021.
Implementation positions Mimetis as Bioprinting Leader
Finally, the implementation of this ambitious project will position Mimetis Biomaterials at the forefront of innovation and development in bioprinting and bone regeneration technologies. Undoubtedly, the information acquired throughout the study will provide essential data for its transfer to clinical use. Therefore, it will change the current treatment paradigm related to personalized regenerative medicine.
Mimetis thanks the support of the European Commission for all its initiative grants. We appreciate specifically its support for this grant obtained via the Maxibone project (H2020-SC1-2017-Single-Stage-RTD; 779322).